பேட்ரீஸ் புலா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பேட்ரீஸ் புலா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பேட்ரீஸ் புலா Today - Breaking & Trending Today

Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Richard Jarvis , Isabella Zinck , Bridgette Heller , Thomas Hungerbuehler , Patrice Bula , Simon Moroney , Samir Shah , Julie Masow , Sloan Simpson , Enrico Vanni , Exchange Commission , Novartis Strategy Financial Communications , Compensation Committee , Joerg Reinhardt , Executive Committee , Annual General Meeting , Independent Proxy , General Meeting , ஒன்றுபட்டது மாநிலங்களில் , ரிச்சர்ட் ஜார்விஸ் , இசபெல்லா ஜினக்க் , பிரிட்ஜெட் ஹெல்லர் , பேட்ரீஸ் புலா , சிமோன் மூரோனி , சமீர் ஷா ,

Novartis International AG: Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

Novartis International AG: Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , Richard Jarvis , Isabella Zinck , Bridgette Heller , Thomas Hungerbuehler , Patrice Bula , Simon Moroney , Samir Shah , Julie Masow , Sloan Simpson , Enrico Vanni , Exchange Commission , Novartis Strategy Financial Communications , Compensation Committee , Joerg Reinhardt , Executive Committee , Annual General Meeting , Independent Proxy , General Meeting , ஒன்றுபட்டது மாநிலங்களில் , ரிச்சர்ட் ஜார்விஸ் , இசபெல்லா ஜினக்க் , பிரிட்ஜெட் ஹெல்லர் , பேட்ரீஸ் புலா , சிமோன் மூரோனி , சமீர் ஷா ,

Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.

13
1Refers to continuing operations as defined on page 43 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions.
2Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
3 Please see detailed guidance assumptions on page 8 including the forecast assumption that we see a continuation of the return to normal global healthcare systems including prescription dynamics by mid 2021. In addition, we assume that no Gilenyaand noSandostatinLAR generics enter in 2021 in the US. ....

United States , Charlesl Sawyers , Bridgette Heller , Bertrand Bodson , Kesimptaandentresto Hfp , Robert Weltevreden , Elizabeth Doherty , Patrice Bula , Nancyc Andrews , Jakavi Gv , Simon Moroney , Promacta Revolade , Frans Van Houten , Joerg Reinhardt , Srikant Datar , Enrico Vanni , Moody Investors Service , Novartis Group , Compensation Committee , Customer Technology Solutions , Novartis Executive Committee On , Alcon Inc , Committee Novartis , Sandoz Division , Committee Of Novartis , International Financial Reporting Standards ,

Novartis International AG: Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.

Novartis International AG: Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.
Pharmaceuticals BU grew 5% (cc) driven by
Entresto (+44% cc),
Cosentyx (+13% cc),
Xiidra acquisition (+95% cc)
Promacta/Revolade (+23% cc),
Piqray (reaching USD 0.3 billion)
Sandoz sales were in line (cc, -1% USD), with Biopharmaceuticals growing 19% (cc)
COVID-19 negatively impacted demand, particularly: ophthalmology, dermatology and Sandoz retail
Core operating income² grew 13% (cc, +9% USD) and Innovative Medicines and Sandoz core margin improved to 35% and 24% of sales respectively, driven by sales growth, lower spend and productivity
Continued transformation of Manufacturing and Business Services contributing to core margin expansion ....

United States , New Zealand , San Antonio , Entresto Hfp , Patrice Bula , Nancyc Andrews , Simon Moroney , Gleevec Glivec , Exjade Jadenu , Charlesl Sawyers , Bridgette Heller , Bertrand Bodson , Elizabeth Doherty , Robert Weltevreden , Jakavi Gv , Promacta Revolade , Frans Van Houten , Joerg Reinhardt , Afinitor Votubia , Srikant Datar , Enrico Vanni , Moody Investors Service , Novartis Group , American College Of Rheumatology , Compensation Committee , American Society Of Hematology ,